Analogy 1: A very early-stage version of a pharmaceutical company like Pfizer or Merck, focused on a few specific drug candidates.

Analogy 2: Like a much smaller Amgen or Eli Lilly, specializing in therapies for rare diseases and biodefense.

Analogy 3: A specialized biotech company, similar to a small, focused research arm of a larger pharmaceutical firm like Johnson & Johnson, dedicated to niche therapies.

• HyBryte™ (synthetic hypericin topical solution): An FDA-approved photodynamic therapy used for the treatment of early-stage cutaneous T-cell lymphoma (CTCL).
• SGX942 (dusquetide): A drug candidate in late-stage clinical development for the treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation.
• RiVax® (ricin toxin vaccine): A biodefense vaccine candidate being developed under federal contracts to protect against the effects of ricin toxin exposure.

Soligenix (SNGX) is a biopharmaceutical company focused on developing and commercializing products for rare diseases and medical countermeasures. As a company primarily in the clinical development stage with specific medical countermeasure programs, its major revenue sources come from government contracts and grants, rather than significant commercial sales of its drugs to traditional companies or directly to individuals.

Based on its financial filings (e.g., 10-K reports), Soligenix's primary "customers" – in the context of its revenue generation and funding of its development programs – are agencies of the U.S. government. These entities fund critical research, development, and potential procurement of medical countermeasures, particularly for programs like RiVax®.

The key U.S. government agencies that serve as major funding partners and "customers" for Soligenix's programs include:

• National Institute of Allergy and Infectious Diseases (NIAID): A component of the National Institutes of Health (NIH), which is an agency within the U.S. Department of Health and Human Services (HHS).
• Biomedical Advanced Research and Development Authority (BARDA): An office within the Administration for Strategic Preparedness and Response (ASPR) of the U.S. Department of Health and Human Services (HHS).

As these are U.S. government agencies, they do not have public company symbols.

• IDT Biologika GmbH - Contract manufacturer for RiVax® (ricin vaccine) and other heat-stable vaccine candidates.
• Thermo Fisher Scientific (Symbol: TMO) - Contract manufacturer for commercial-scale manufacturing and filling processes for Soligenix's heat-stable vaccine platform, including RiVax®.

Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer

Dr. Schaber has over 30 years of experience in the pharmaceutical and biotechnology industry and has served as President and Chief Executive Officer of Soligenix since August 2006, and Chairman of the Board since October 2009. He co-founded Acute Therapeutics, Inc. (1996-1998), where he was Vice President of Regulatory Compliance and Drug Development. Prior to Soligenix, he was Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc. from 1998 to 2006. Throughout his career, Dr. Schaber has been instrumental in raising over $300 million through public and private placements, and more than $80 million through government grants and contracts. He also had a "nice exit" from a company he helped co-found.

Jonathan Guarino, CPA Senior Vice President and Chief Financial Officer

Mr. Guarino brings over 25 years of experience in financial and strategic management, particularly in the life sciences industry. He has been the Senior Vice President and Chief Financial Officer of Soligenix since 2019. His previous roles include Corporate Controller for Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.), where he helped establish the financial infrastructure and contributed to capital fundraising and debt financings. He also served as Corporate Controller for Suite K Value Added Services LLC and as Senior Manager of Technical Accounting at Covance Inc.

Oreola Donini, PhD Senior Vice President and Chief Scientific Officer

Dr. Donini possesses over 20 years of experience in drug discovery and preclinical development, primarily with start-up biotechnology companies. She has been crucial in advancing several novel therapies from early-stage development into clinical trials. Dr. Donini previously held positions at ESSA Pharma Inc., Inimex Pharmaceuticals Inc., and Kinetek Pharmaceuticals Inc. She is a co-inventor and leader of the SGX94 innate defense regulator technology, which was initially developed by Inimex Pharmaceuticals and later acquired by Soligenix.

Richard C. Straube, MD, MSc Chief Medical Officer

Dr. Straube has more than 35 years of experience in both academic and industry settings. He is a board-certified pediatrician with a focus on clinical research in host-response modulation. Dr. Straube currently serves as a Chief Medical Officer Consultant for Soligenix. His prior leadership roles include Chief Medical Officer at Stealth Peptides Incorporated (since 2009) and Critical Biologics Corporation (2007-2009). He also served as Chief Scientific Officer and Vice President of Research and Development at INO Therapeutics LLC, and held senior positions in clinical research at Centocor Inc. and Ohmeda Corp.

Soligenix (SNGX) operates in two main segments: Specialized BioTherapeutics and Public Health Solutions. The addressable markets for their main products are as follows:

Specialized BioTherapeutics

• HyBryte™ (SGX301) for Cutaneous T-Cell Lymphoma (CTCL):
  • The total addressable worldwide CTCL market is estimated at greater than $250 million annually.
  • The global CTCL market size was valued at USD 496 million in 2025 and is projected to reach USD 958.9 million by the end of 2035.
  • Another estimate for the global CTCL market valued it at USD 2,375.61 million in 2024, expected to increase to USD 3,439.74 million by 2031.
  • The addressable U.S. market for CTCL is approximately 3,000 patients, representing a USD 400 million revenue opportunity.
  • Peak annual net sales of HyBryte™ in the U.S. are expected to exceed $90 million.
• SGX302 for Mild-to-Moderate Psoriasis:
  • The total addressable worldwide psoriasis market opportunity with SGX302 is estimated to exceed $1 billion annually.
  • In the U.S. alone, the mild-to-moderate psoriasis market has a total addressable market of over a billion, with approximately 3 million patients.
• SGX942 for Oral Mucositis in Head and Neck Cancer:
  • The oral mucositis market is expected to reach USD 1.03 billion in 2025 and grow to USD 1.44 billion by 2030 globally.
  • Globally, the oral mucositis market size is projected to grow from $1.51 billion in 2024 to $1.63 billion in 2025, and further to $2.08 billion in 2029.
  • North America was the largest region in the oral mucositis market in 2024.
  • The estimated size for oral mucositis in head and neck cancer is half a billion (U.S.).
• SGX945 for Behçet's Disease:
  • The worldwide market opportunity for SGX945 in Behçet's disease is estimated at approximately $200 million annually.

Public Health Solutions

• RiVax® (Ricin Toxin Vaccine Candidate) and other Public Health Offerings (SGX943, CiVax™, Filovirus Vaccines):
  • The market for these products primarily involves government procurement contracts for biodefense solutions.
  • No specific dollar value for the addressable market size has been provided in the search results.
  • Addressable Market Size: null

Soligenix (SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases. The company's future revenue growth over the next 2-3 years is expected to be driven by advancements and potential commercialization of its key pipeline assets and continued government funding for its public health solutions.

Here are the primary expected drivers of future revenue growth:

1. Commercialization of HyBryte™ (SGX301) for Cutaneous T-Cell Lymphoma (CTCL): HyBryte™ is Soligenix's most advanced product, a novel photodynamic therapy for early-stage cutaneous T-cell lymphoma (CTCL). Top-line results from the confirmatory Phase 3 study (FLASH2) for HyBryte™ are anticipated in the second half of 2026. Successful completion of this study and subsequent regulatory approvals would pave the way for potential worldwide commercialization. The company projects peak annual net sales of HyBryte™ in the U.S. to exceed $90 million, with the total global CTCL market estimated at over $250 million annually.
2. Expansion of Synthetic Hypericin (SGX302) into Psoriasis: Soligenix is developing SGX302, which utilizes the same active ingredient as HyBryte™, for the treatment of mild-to-moderate psoriasis. Top-line Phase 2a results for SGX302 in psoriasis are expected in the fourth quarter of 2025. The worldwide psoriasis market opportunity for SGX302 is estimated to exceed $1 billion annually, representing a significant potential revenue stream if clinical development is successful.
3. Advancement of Innate Defense Regulator (IDR) Technology (Dusquetide - SGX942/SGX945) programs: The company's innate defense regulator (IDR) technology includes dusquetide, with SGX945 in development for Behçet's Disease and SGX942 for oral mucositis in head and neck cancer. SGX945 has already successfully completed a Phase 2a proof-of-concept study in Behçet's Disease, demonstrating biological efficacy. Top-line results from ongoing Phase 2 studies for SGX945 in Behçet's disease are anticipated in the second half of 2025.
4. Government Grants and Contracts for Public Health Solutions: Soligenix's Public Health Solutions business segment includes vaccine candidates like RiVax® (ricin toxin vaccine), and programs targeting filoviruses (such as Marburg and Ebola) and CiVax™ (COVID-19). These programs are supported by government grants and contracts from agencies such as the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). Continued funding and progress in these biodefense and infectious disease programs are expected to contribute to the company's revenue.

Share Issuance

• In April 2024, Soligenix announced the pricing of a public offering of 11,875,000 shares of common stock (or common stock equivalents) and warrants, generating approximately $4.75 million in gross proceeds to fund research and development, commercialization activities, and for general corporate and working capital purposes.
• In June 2024, the company completed a one-for-sixteen reverse stock split of its common stock to enhance share liquidity.
• In September 2025, Soligenix closed a public offering, raising approximately $7.5 million in gross proceeds from the sale of 5,555,560 shares of common stock (or equivalents) and warrants. This funding is intended to extend the company's cash runway through the end of 2026 and support research and development, commercialization activities, working capital, and general corporate purposes.

Inbound Investments

• Soligenix's Public Health Solutions business segment has been supported by government grant and contract funding from organizations such as the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).

Capital Expenditures

• Capital expenditures for Soligenix have been minimal, with a reported -$3,921 over the last 12 months.
• The company's primary focus for resource allocation is advancing its multiple clinical programs, including ongoing Phase 2 and Phase 3 studies for its product candidates like HyBryte™ (SGX301), SGX945 (dusquetide), and SGX302 (synthetic hypericin).